Johnson & Johnson (JNJ) Prepaid Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Prepaid Assets of $4.8 billion for Q2 2026, little changed sequentially from $4.8 billion in Q1 2026, and up 10.69% YoY from $4.4 billion in Q2 2025.
Johnson & Johnson (JNJ) Prepaid Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Prepaid Assets for 18 years, with the latest figure at $4.8 billion in Q2 2026.
- Quarterly Prepaid Assets rose 10.69% year-over-year to $4.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.8 billion (up 10.69% YoY) and the FY2025 annual result came in at $4.2 billion, up 1.66% from the prior year.
- Prepaid Assets held at $4.8 billion in Q2 2026 per JNJ's latest filing, from $4.8 billion in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.8 billion in Q2 2026 and troughed at $2.4 billion in Q3 2023.
- A 5-year average of $3.9 billion and a median of $4.2 billion in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets plunged 35.27% in 2023, then soared 82.69% in 2024.
- Over 5 years, Prepaid Assets stood at $3.6 billion in 2022, then grew by 25.67% to $4.5 billion in 2023, then fell by 9.5% to $4.1 billion in 2024, then gained by 1.66% to $4.2 billion in 2025, then gained by 16.21% to $4.8 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.8 billion, $4.8 billion, and $4.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 4.83 Bn |
| Mar 29, 2026 | 4.82 Bn |
| Dec 28, 2025 | 4.15 Bn |
| Sep 28, 2025 | 4.29 Bn |
| Jun 29, 2025 | 4.36 Bn |
| Mar 30, 2025 | 4.09 Bn |
| Dec 29, 2024 | 4.09 Bn |
| Sep 29, 2024 | 4.18 Bn |
| Jun 30, 2024 | 4.38 Bn |
| Mar 31, 2024 | 4.46 Bn |
| Dec 31, 2023 | 4.51 Bn |
| Oct 1, 2023 | 4.20 Bn |
| Jul 2, 2023 | 2.40 Bn |
| Apr 2, 2023 | 2.92 Bn |
| Jan 1, 2023 | 2.88 Bn |
| Oct 2, 2022 | 3.59 Bn |
| Jul 3, 2022 | 3.70 Bn |
| Apr 3, 2022 | 3.45 Bn |
| Jan 2, 2022 | 3.70 Bn |
| Oct 3, 2021 | 3.59 Bn |